Profusa, Inc. (NASDAQ:PFSA) Shares Shorted: Short Interest Down 51.5% in October

Profusa, Inc. (NASDAQ:PFSA) saw a significant decline in short interest in October. As of October 15th, there was short interest totaling 77,845 shares, a decline of 51.5% from the September 30th total of 160,653 shares. Currently, 15.1% of the shares of the stock are sold short. Based on an average daily volume of 645,641 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Profusa to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings upgraded shares of Profusa from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Insider Buying and Selling

In other Profusa news, major shareholder Financial Lp Hrt sold 10,602 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $3.56, for a total transaction of $37,743.12. Following the sale, the insider directly owned 18,549 shares of the company’s stock, valued at approximately $66,034.44. This represents a 36.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 15.00% of the stock is currently owned by corporate insiders.

Profusa Stock Performance

Shares of PFSA stock traded down $0.07 during mid-day trading on Friday, hitting $0.70. The company’s stock had a trading volume of 161,331 shares, compared to its average volume of 2,742,092. The company’s fifty day simple moving average is $2.07 and its 200-day simple moving average is $100.73. The company has a market cap of $427,061.00, a PE ratio of -0.00 and a beta of 0.53. Profusa has a 52 week low of $0.69 and a 52 week high of $1,962.75.

Profusa (NASDAQ:PFSA) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($151.80) EPS for the quarter.

Profusa Company Profile

Profusa, Inc is a biotechnology and medical-device company focused on developing implantable biosensors designed to continuously monitor biochemical conditions inside the body. Its technology is intended to provide real-time health data without requiring repeated blood draws or external sampling.

The company’s biosensors are designed to be placed under the skin and remain in the body while communicating measurements to an external reader or connected device. Profusa has developed platforms intended to monitor markers such as tissue oxygen levels, with potential applications in areas including peripheral artery disease, wound care, chronic disease management and clinical research.

Profusa’s technology combines a small, injectable hydrogel sensor with optical detection and wireless data transmission.